Items where authors include "Davis, J.D."

Article

Paller, A.S., Siegfried, E.C., Simpson, E.L. et al. (12 more authors) (2021) A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Journal of the European Academy of Dermatology and Venereology, 35 (2). pp. 464-475. ISSN 0926-9959

Paller, A.S., Siegfried, E.C., Thaçi, D. et al. (22 more authors) (2020) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology, 83 (5). pp. 1282-1293. ISSN 0190-9622

Cork, M.J. orcid.org/0000-0003-4428-2428, Thaçi, D., Eichenfield, L.F. et al. (19 more authors) (2020) Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis : results from a phase IIa open‐label trial and subsequent phase III open‐label extension. British Journal of Dermatology, 182 (1). pp. 85-96. ISSN 0007-0963

Akinlade, B., Guttman-Yassky, E., de Bruin-Weller, M. et al. (25 more authors) (2019) Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology, 181 (3). pp. 459-473. ISSN 0007-0963

Proceedings Paper

Cork, M.J. orcid.org/0000-0003-4428-2428, Eichenfield, L.F., Blauvelt, A. et al. (9 more authors) (2019) 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. In: Journal of Investigative Dermatology. Society for Investigative Dermatology (SID) 2019, 08-11 May 2019, Hilton Chicago, Chicago, Illinois. Elsevier , S104-S104.